Titre
Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Laaboub, N.
Auteure/Auteur
Dubath, C.
Auteure/Auteur
Ranjbar, S.
Auteure/Auteur
Sibailly, G.
Auteure/Auteur
Grosu, C.
Auteure/Auteur
Piras, M.
Auteure/Auteur
Délessert, D.
Auteure/Auteur
Richard-Lepouriel, H.
Auteure/Auteur
Ansermot, N.
Auteure/Auteur
Crettol, S.
Auteure/Auteur
Vandenberghe, F.
Auteure/Auteur
Grandjean, C.
Auteure/Auteur
Delacrétaz, A.
Auteure/Auteur
Gamma, F.
Auteure/Auteur
Plessen, K.J.
Auteure/Auteur
von Gunten, A.
Auteure/Auteur
Conus, P.
Auteure/Auteur
Eap, C.B.
Auteure/Auteur
ISSN
1471-244X
Statut éditorial
Publié
Date de publication
2022-05-17
Volume
22
Numéro
1
Première page
342
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Résumé
Insomnia disorders as well as cardiometabolic disorders are highly prevalent in the psychiatric population compared to the general population. We aimed to investigate their association and evolution over time in a Swiss psychiatric cohort.
Data for 2861 patients (8954 observations) were obtained from two prospective cohorts (PsyMetab and PsyClin) with metabolic parameters monitored routinely during psychotropic treatment. Insomnia disorders were based on the presence of ICD-10 "F51.0" diagnosis (non-organic insomnia), the prescription of sedatives before bedtime or the discharge letter. Metabolic syndrome was defined using the International Diabetes Federation definition, while the 10-year risk of cardiovascular event or death was assessed using the Framingham Risk Score and the Systematic Coronary Risk Estimation, respectively.
Insomnia disorders were observed in 30% of the cohort, who were older, predominantly female, used more psychotropic drugs carrying risk of high weight gain (olanzapine, clozapine, valproate) and were more prone to suffer from schizoaffective or bipolar disorders. Multivariate analyses showed that patients with high body mass index (OR = 2.02, 95%CI [1.51-2.72] for each ten-kg/m <sup>2</sup> increase), central obesity (OR = 2.20, [1.63-2.96]), hypertension (OR = 1.86, [1.23-2.81]), hyperglycemia (OR = 3.70, [2.16-6.33]), high density lipoprotein hypocholesterolemia in women (OR = 1.51, [1.17-1.95]), metabolic syndrome (OR = 1.84, [1.16-2.92]) and higher 10-year risk of death from cardiovascular diseases (OR = 1.34, [1.17-1.53]) were more likely to have insomnia disorders. Time and insomnia disorders were associated with a deterioration of cardiometabolic parameters.
Insomnia disorders are significantly associated with metabolic worsening and risk of death from cardiovascular diseases in psychiatric patients.
Data for 2861 patients (8954 observations) were obtained from two prospective cohorts (PsyMetab and PsyClin) with metabolic parameters monitored routinely during psychotropic treatment. Insomnia disorders were based on the presence of ICD-10 "F51.0" diagnosis (non-organic insomnia), the prescription of sedatives before bedtime or the discharge letter. Metabolic syndrome was defined using the International Diabetes Federation definition, while the 10-year risk of cardiovascular event or death was assessed using the Framingham Risk Score and the Systematic Coronary Risk Estimation, respectively.
Insomnia disorders were observed in 30% of the cohort, who were older, predominantly female, used more psychotropic drugs carrying risk of high weight gain (olanzapine, clozapine, valproate) and were more prone to suffer from schizoaffective or bipolar disorders. Multivariate analyses showed that patients with high body mass index (OR = 2.02, 95%CI [1.51-2.72] for each ten-kg/m <sup>2</sup> increase), central obesity (OR = 2.20, [1.63-2.96]), hypertension (OR = 1.86, [1.23-2.81]), hyperglycemia (OR = 3.70, [2.16-6.33]), high density lipoprotein hypocholesterolemia in women (OR = 1.51, [1.17-1.95]), metabolic syndrome (OR = 1.84, [1.16-2.92]) and higher 10-year risk of death from cardiovascular diseases (OR = 1.34, [1.17-1.53]) were more likely to have insomnia disorders. Time and insomnia disorders were associated with a deterioration of cardiometabolic parameters.
Insomnia disorders are significantly associated with metabolic worsening and risk of death from cardiovascular diseases in psychiatric patients.
Sujets
PID Serval
serval:BIB_2E9824076089
PMID
Open Access
Oui
Date de création
2022-05-31T12:05:57.825Z
Date de création dans IRIS
2025-05-20T17:49:27Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
s12888-022-03983-3.pdf
Version du manuscrit
published
Licence
https://creativecommons.org/licenses/by/4.0
Taille
967.65 KB
Format
Adobe PDF
PID Serval
serval:BIB_2E9824076089.P001
URN
urn:nbn:ch:serval-BIB_2E98240760893
Somme de contrôle
(MD5):28b980e251796e09a3b6d5482e8180ef